Drug Manufacturers Should Expect No Relief From China’s Rising API Prices
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - API prices in China have increased since the end of last year, and prices are expected to continue to rise with the addition of new costs associated with stronger environmental protection standards, according to analysts
You may also be interested in...
Vietnam To Boost Pharma Industry; Key MOU Signed Between Ministries
Vietnam's Ministry of Public Health and the Ministry of Industry and Trade signed a memorandum of understanding to develop the country's pharmaceutical industry and stabilize the country's pharmaceutical market
Vietnam To Boost Pharma Industry; Key MOU Signed Between Ministries
Vietnam's Ministry of Public Health and the Ministry of Industry and Trade signed a memorandum of understanding to develop the country's pharmaceutical industry and stabilize the country's pharmaceutical market
China Shenghuo Sees Sales Boost In Rural Markets From New Health Care Reform And Expanding Retail Cosmetics
SHANGHAI - China Shenghuo Pharmaceutical saw sales growth in China's rural areas thanks to new medical reforms in China during the first nine months of 2008, company President Lan Feng told a Nov. 25 earnings call